The Oncology Deep Dive

The Oncology Deep Dive

The Oncology Deep Dive is your weekly briefing on the most important cancer research, turned into clear, jargon-free conversations. Each episode distills new trial data, FDA decisions, and industry moves from across oncology into an accessible discussion for clinicians, investors, and curious listeners alike. Disclaimer: AI-generated from publicly available news. Not medical or investment advice. May contain errors — verify against primary sources.

Folgen

  1. vor 8 Std.

    Same Molecule, Different Road: How a Logistics Company Took On Novartis in the Radioligand Race | Plus Lilly's Breast Cancer Moat & Europe's Regulatory Wave

    Three stories dominated oncology this week — and each one redefines what it takes to win. First, Eli Lilly's FDA approval of imlunestrant locks down ESR1-mutated breast cancer with a clinical moat that AstraZeneca's failed SERENA-4 trial couldn't crack, while Roche pivots to a tolerability play in early-stage disease. Then, Curium's Bexlutry shatters Novartis's radioligand monopoly using the exact same molecule, proving that in the age of decaying isotopes, logistics can trump R&D. Finally, five CHMP recommendations out of Europe reshape the competitive map — from Enhertu's leap into curative-intent adjuvant therapy to a Keytruda–Padcev combination that slams the door on bladder cancer competitors. Plus a lightning round covering Amgen access wins, GSK's $750M myeloma deal, and a wave of stealth trial registrations signaling a defensive land grab across lung and breast cancer. Disclaimer: AI-generated from publicly available news. Not medical or investment advice. May contain errors — verify against primary sources. (00:00) Introduction & What's Ahead This Week (00:52) Lilly's Imlunestrant: FDA Approval & the ESR1 Mutation (01:38) How Tumors Outsmart Hormone Therapy (02:30) SERDs: A New Mechanism of Action (02:53) EMBER-3 Trial Results — Doubling Progression-Free Survival (03:38) AstraZeneca's SERENA-4 Failure & Lilly's Clinical Moat (04:46) Roche's Strategic Pivot to Early-Stage Breast Cancer (05:59) Curium's Bexlutry vs. Novartis's Lutathera (06:30) How Radioligand Therapies Work (07:17) The 505(b)(2) Pathway — Regulatory Shortcut or Disruption? (08:32) The Supply Chain Battle — Decaying Isotopes & Logistics (10:21) What Bexlutry Means for Radiopharmaceutical Investment (11:03) Europe's Regulatory Wave — Five CHMP Recommendations (11:49) Enhertu's Leap from Palliative to Curative Intent (13:52) PARP Inhibitor Commoditization vs. Market Lock-Out (15:29) Keytruda + Padcev Corner the Bladder Cancer Market (16:13) Lightning Round — Five Headlines in Five Minutes (17:43) Closing: The Evolving Definition of a Commercial Moat

  2. vor 6 Tagen

    Ivonescimab Beats Keytruda: Oncology's Biggest Data Weekend

    What happens when a cancer drug works exactly as designed — stops the tumor for months — but the patient dies sooner? That paradox runs through the biggest oncology dataweekend of the year. We distill the data drop from the World Conference on Lung Cancer (WCLC) in Seoul: Ivonescimab beating Keytruda head-to-head in first-line non-small cell lung cancer, theDESTINY-Lung04 survival paradox, two same-day breakthroughs that revived smallcell lung cancer after decades of stagnation, and what the wave of genericsmeans for the oncology "blockbuster." We cut through the jargon on bispecific antibodies, antibody-drug conjugates, and BiTEs — and why sequencing may now matter as much as the drug itself. Disclaimer:AI-generated from publicly available news. Not medical or investment advice.May contain errors — verify against primary sources. 00:00 The Survival Paradox 00:32 Welcome to the Deep Dive 01:19 HARMONI-2: Ivonescimab vs Keytruda 02:25 How Bispecific Antibodies Work 03:13 The Survival Numbers 04:18 The Single-Region Trial Caveat 05:18 Merck's Response 06:04 DESTINY-Lung04: The Paradox 06:40 How Antibody-Drug Conjugates Work 08:10 Why the Survival Paradox Happens 09:29 A Curveball: Sevabretinib 11:10 RESILIENT-3: Cullinan vs J&J 14:37 Small Cell: The Graveyard Awakens 16:12 Amgen's BiTE: Molecular Handcuffs 17:09 Sequencing, Not Competing 18:08 Diagnostics & Disease Interception 19:38 Where the Venture Capital Flows 20:22 The Generics Reality Check 21:07 The End of the Blockbuster Era?

  • 2 Folgen

Info

The Oncology Deep Dive is your weekly briefing on the most important cancer research, turned into clear, jargon-free conversations. Each episode distills new trial data, FDA decisions, and industry moves from across oncology into an accessible discussion for clinicians, investors, and curious listeners alike. Disclaimer: AI-generated from publicly available news. Not medical or investment advice. May contain errors — verify against primary sources.

Informationen

  • Erstellt von
    The Oncology Deep Dive
  • Jahre aktiv
    2026
  • Folgen
    2
  • Bewertung
    Unbedenklich
  • Copyright
    © The Oncology Deep Dive
  • Sendungswebsite
    The Oncology Deep Dive